Recently, TG Therapeutics (TGTX) reported positive results from its Phase 2b registrational directed trial UNITY-NHL study. Updated results from this study were presented at AACR earlier this year, and most recently at ASCO. For my previous coverage of TGTX, I recommend reading my complete company overview here, and then . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.